Internacional (Marketwired, 08 de Agosto de 2013) Approximately 3.3 Million Shares Shorted Since December 2012; Short Squeeze Expected When Stock Closes Above $6.99 SqueezeTrigger PriceAtossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, announced today that BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Atossa Genetics after releasing the latest short sale data through August 6, 2013. The total aggregate number of shares shorted since December 2012 is approximately 3.3 million shares. Approximately 23.99% of daily trading volume is short selling. The SqueezeTrigger price for all ATOS shares shorted is $6.99. A short squeeze is expected when ATOS closes above its $6.99 SqueezeTrigger price.
Click here to view Report: http://www.buyins.com/reports/atos8-7-13.pdf
Click here for SqueezeTrigger: http://www.buyins.com/images2/atosstr8-7-13.jpg
Click here for Friction Factor: http://www.buyins.com/images2/atosff8-7-13.jpg
Click here for detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of ATOS. 38% of the previous 39 trading days have been positive or bullish-biased and 62% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors ATOS market-makers daily for compliance with Fair Market-Making Requirements.
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor — market-maker surveillance system tracking market-makers to determine Price Friction and compliance with new "Fair Market-Making Requirements."
RegSHO Naked Shorts — tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger — 37 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge — predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality — predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader — tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scanner — automates tracking of technical patterns and predicts next move in stocks.
GATS — tracks all strategies
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Buyins.net has been paid $1,116 per month for data provided in twelve monthly reports. ATOS has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Atossa Genetics, Inc.
CFO and General Counsel